Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ding Ma
Observed name:
Ma, Ding
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center
ORCID:
0009-0000-4890-6424
Observed ORCID:
0009-0000-4890-6424
OpenAlex ID:
A5060584516
Molecular classification of hormone receptor-positive HER2-negative breast cancer
2023
·
Xi Jin
, Yi-Fan Zhou
, et al.
·
Nature Genetics
·
137
Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities
2024
·
Yi-Zhou Jiang
, Ding Ma
, et al.
·
Nature Cancer
·
130
Single-cell morphological and topological atlas reveals the ecosystem diversity of human breast cancer
2023
·
Shen Zhao
, De-Pin Chen
, et al.
·
Nature Communications
·
93
PDF
Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2024
·
Yu-Wei Li
, Lei-Jie Dai
, et al.
·
Cancer Research
·
78
Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer
2023
·
Lei-Jie Dai
, Ding Ma
, et al.
·
Nature Communications
·
76
PDF
Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial
2025
·
Song-Yang Wu
, Xi Jin
, et al.
·
Nature Medicine
·
58
Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer
2023
·
Wen-Ting Peng
, Xi Jin
, et al.
·
Cancer Research
·
34
Calcification-associated molecular traits and therapeutic strategies in hormone receptor-positive HER2-negative breast cancer
2024
·
Yuwei Li
, Yuzheng Xu
, et al.
·
Cancer Biology and Medicine
·
4
PDF
Spatially interpretable artificial intelligence framework to tailored neoadjuvant dual HER2 blockade in HER2-positive breast cancer
2026
·
Xiang-Rong Wu
, Hong Lv
, et al.
·
Signal Transduction and Targeted Therapy
·
3
PDF
Multiomics Profiling Characterizes Distinct HER2-Low Breast Cancer Subgroups in the East Asian Population
2022
·
Leijie Dai
, Ding Ma
, et al.
·
SSRN Electronic Journal
·
2
Decoding neutrophil spatial heterogeneity and clinical implications in breast cancer
2026
·
Yu-Zheng Xu
, Xiang-Rong Wu
, et al.
·
Cancer Cell
·
1
Data from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2024
·
Yu-Wei Li
, Lei-Jie Dai
, et al.
·
1
Abstract HER2-09: HER2-09 Multiomics Profiling Characterizes Distinct HER2-low Breast Cancer Subgroups in the East Asian Population
2023
·
Lei-Jie Dai
, Ding Ma
, et al.
·
Cancer Research
·
1
A comprehensive genomic and transcriptomic dataset of triple-negative breast cancers
2022
·
Chen, Qingwang
, Liu, Yaqing
, et al.
·
Figshare
·
1
Table S2 from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2026
·
Yu-Wei Li
, Lei-Jie Dai
, et al.
Figure S6 from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2026
·
Yu-Wei Li
, Lei-Jie Dai
, et al.
Figure S4 from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2026
·
Yu-Wei Li
, Lei-Jie Dai
, et al.
Figure S2 from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2026
·
Yu-Wei Li
, Lei-Jie Dai
, et al.
Figure S5 from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2026
·
Yu-Wei Li
, Lei-Jie Dai
, et al.
Table S3 from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2026
·
Yu-Wei Li
, Lei-Jie Dai
, et al.
Figure S7 from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2026
·
Yu-Wei Li
, Lei-Jie Dai
, et al.
Table S5 from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2026
·
Yu-Wei Li
, Lei-Jie Dai
, et al.
Table S1 from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2026
·
Yu-Wei Li
, Lei-Jie Dai
, et al.
Figure S1 from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2026
·
Yu-Wei Li
, Lei-Jie Dai
, et al.
Figure S3 from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2026
·
Yu-Wei Li
, Lei-Jie Dai
, et al.
Show more works
View as search
Works count:
49
Citation count:
619
H-index:
7
I10-index:
7
Year
Topic
Type